Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

3-6 months≤5 visitsSafety phase (I)Efficacy phase (II)No PlaceboCost ReimbursementStandard MedicinesOralOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Ipnolor

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Lormetazepam
Lormetazepam is a substance that helps people fall asleep and stay asleep for short-term treatment of insomnia.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Aldosomnil
Axilium
Ergocalm

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Leon Berard
#250003: Oncologie Medicale
Meyzieu, France
Hopital Saint Louis
#250001: Dermatologie
Quinze-Vingts, France
Institut Gustave Roussy
#250002: Oncologie Medicale
Villejuif, France
Sponsor: Ipsen Pharma
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.